Case 18-2008: A 68-year-old man with headache and visual changes after liver transplantation

New England Journal of Medicine

Volumn 358, Issue 24, 2008, Pages 2619-

  Seton, Margaret ^a,b   Pless, Misha ^a,b   Fishman, Jay A ^a,b   Caruso, Paul A ^a,b,c   Hedley Whyte, E Tessa ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; CEFEPIME; CORTICOSTEROID; FLUCONAZOLE; FUROSEMIDE; METHYLPREDNISOLONE; OXYCODONE; PARACETAMOL; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; SPIRONOLACTONE; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN;

AGED; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD VESSEL BIOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; ENCEPHALITIS; FACIAL NERVE; FACIAL NERVE PARALYSIS; GIANT CELL ARTERITIS; HEADACHE; HEPATITIS C VIRUS; HUMAN; ISCHEMIC OPTIC NEUROPATHY; LABORATORY DIAGNOSIS; LABORATORY TEST; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; NEUROIMAGING; OPHTHALMOSCOPY; OPPORTUNISTIC INFECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TEMPORAL ARTERY; THROMBUS; VISUAL IMPAIRMENT; ANEURYSM; ANEURYSM RUPTURE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; FATALITY; HEPATITIS C; IMMUNE DEFICIENCY; INFARCTION; INTRACRANIAL ANEURYSM; MICROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PARANASAL SINUS DISEASE; PATHOLOGY; VASCULARIZATION; VISUAL DISORDER;

AGED; ANEURYSM, INFECTED; ANEURYSM, RUPTURED; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; GIANT CELL ARTERITIS; HEADACHE; HEPATITIS C; HUMANS; IMMUNOCOMPROMISED HOST; INFARCTION; INTRACRANIAL ANEURYSM; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; OPTIC NERVE; PARANASAL SINUS DISEASES; TEMPORAL ARTERIES; VISION DISORDERS;

EID: 45149111061     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0802849     Document Type: Article

References (32)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
2. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.
3. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis Rheum 1990;33:1065-7.
4. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001;45:140-5.
5. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
6. Jover JA, Hernández-Garcia C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.
7. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550-5.
8. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098-103.
9. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003;110:1204-15.
10. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001;85:1061-4.
11. Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997;104:854-8.
12. Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-85.
13. Généreau T, Martin A, Lortholary O, Nöel V, Guillevin L. Temporal arteritis symptoms in a patient with hepatitis C virus associated type II cryoglobulinemia and small vessel vasculitis. J Rheumatol 1998;25:183-5.
14. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 2004;31:1467.
15. Hoffman GS. Treatment of giant-cell arteritis: where we have been and why we must move on. Cleve Clin J Med 2002;69:Suppl 2:SII-117-SII-120.
16. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631-9.
17. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30.
18. Atkison PR, Joubert GI, Guiraudon C, et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation 1997;64:773-5.
19. Gunji Y, Ochiai T, Sakamoto K, et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. Transplant Proc 1993;25:752-3.
20. Tsamandas AC, Jain AB, Felekouras ES, Fung JJ, Demetris AJ, Lee RG. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation 1997;64:252-7.
21. Pizzolato GP, Sztajzel R, Burkhardt K, Megret M, Borisch B. Cerebral vasculitis during FK 506 treatment in a liver transplant patient. Neurology 1998;50:1154-7.
22. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 1981;70:405-11.
23. Fishman JA. Infections in solid organ transplantation. N Engl J Med 2007;357:2601-14.
24. Case Records of the Massachusetts General Hospital (Case 11-2008). N Engl J Med 2008;358:1604-13.
25. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006;6:386-91.
26. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004;23:1376-81.
27. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003;37:221-9.
28. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003;17:113-34.
29. Fishman JA. Overview: fungal infections in the transplant patient. Transpl Infect Dis 2002;4:Suppl 3:3-11.
30. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926-34.
31. Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 1995;106:38-48.
32. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997;64:716-20.